Catalyst Pharmaceuticals (CPRX) Competitors $23.23 +0.43 (+1.89%) Closing price 04:00 PM EasternExtended Trading$23.15 -0.08 (-0.34%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CPRX vs. RDY, MRNA, VTRS, QGEN, ASND, ROIV, LNTH, TGTX, RVMD, and BBIOShould you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Catalyst Pharmaceuticals vs. Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Dr. Reddy's Laboratories (NYSE:RDY) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends. Which has better valuation and earnings, RDY or CPRX? Dr. Reddy's Laboratories has higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$311.31B0.04$668M$0.6321.17Catalyst Pharmaceuticals$491.73M5.74$71.41M$1.3117.73 Do insiders & institutionals hold more shares of RDY or CPRX? 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor RDY or CPRX? Catalyst Pharmaceuticals received 183 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 75.11% of users gave Catalyst Pharmaceuticals an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Catalyst PharmaceuticalsOutperform Votes50475.11% Underperform Votes16724.89% Is RDY or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 31.01% compared to Dr. Reddy's Laboratories' net margin of 17.25%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Dr. Reddy's Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% Catalyst Pharmaceuticals 31.01%40.79%34.87% Do analysts rate RDY or CPRX? Dr. Reddy's Laboratories currently has a consensus target price of $17.00, indicating a potential upside of 27.48%. Catalyst Pharmaceuticals has a consensus target price of $32.29, indicating a potential upside of 38.98%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has more risk and volatility, RDY or CPRX? Dr. Reddy's Laboratories has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Does the media refer more to RDY or CPRX? In the previous week, Catalyst Pharmaceuticals had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 14 mentions for Catalyst Pharmaceuticals and 11 mentions for Dr. Reddy's Laboratories. Catalyst Pharmaceuticals' average media sentiment score of 1.29 beat Dr. Reddy's Laboratories' score of 0.98 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Catalyst Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCatalyst Pharmaceuticals beats Dr. Reddy's Laboratories on 16 of the 19 factors compared between the two stocks. Remove Ads Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPRX vs. The Competition Export to ExcelMetricCatalyst PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.82B$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio19.696.7921.7317.81Price / Sales5.74225.96379.2094.61Price / Cash10.7265.6738.1534.64Price / Book7.045.866.464.00Net Income$71.41M$141.86M$3.20B$247.23M7 Day Performance8.55%8.98%6.54%7.26%1 Month Performance10.51%-12.65%-8.55%-6.26%1 Year Performance50.94%-11.99%10.33%-0.18% Catalyst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPRXCatalyst Pharmaceuticals4.6031 of 5 stars$23.23+1.9%$32.29+39.0%+49.8%$2.82B$491.73M19.6980Positive NewsRDYDr. Reddy's Laboratories3.3519 of 5 stars$12.59+1.8%$17.00+35.1%-7.2%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.259 of 5 stars$25.64+2.1%$59.00+130.1%-74.5%$9.91B$3.20B-2.763,900Gap DownVTRSViatris2.9677 of 5 stars$7.61-0.1%$10.50+38.0%-32.7%$9.08B$14.74B-10.2837,000News CoverageHigh Trading VolumeQGENQiagen3.483 of 5 stars$40.33+5.4%$47.71+18.3%+8.3%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.3124 of 5 stars$140.14-1.8%$204.64+46.0%+6.5%$8.50B$363.64M-19.741,017News CoveragePositive NewsGap DownROIVRoivant Sciences2.6317 of 5 stars$9.26-2.1%$17.50+89.0%-6.9%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.3411 of 5 stars$95.45+5.0%$129.43+35.6%+68.0%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3148 of 5 stars$37.25-0.3%$40.67+9.2%+171.3%$5.85B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.816 of 5 stars$31.40+0.3%$65.23+107.7%+1.1%$5.84B$742,000.00-8.75250Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.5716 of 5 stars$30.67-2.2%$52.64+71.6%+29.9%$5.83B$221.90M-10.76400Analyst ForecastGap Down Remove Ads Related Companies and Tools Related Companies RDY Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives ROIV Alternatives LNTH Alternatives TGTX Alternatives RVMD Alternatives BBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CPRX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPRX Stock Free CPRX Stock Alerts